1
/
의
1
AntibodySystem
SKU(재고 관리 코드):DHE26399
Polatuzumab vedotin-piiq (ADC)
Polatuzumab vedotin-piiq (ADC)
Catalog No.: DHE26399
| Catalog No. | DHE26399 |
|---|---|
| Product name | Polatuzumab vedotin-piiq (ADC) |
| Size | 5 mg |
| Species reactivity | Human |
| Applications | Research Grade Biosimilar |
| Description | Polatuzumab vedotin (Polivy) is an ADC consisting of a CD79b-directed antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamustine and rituximab for the treatment of adult patients with at least two relapses or refractory diffuse large B-cell lymphoma. Polatuzumab vedotin binds to CD79b and is internalized by tumor cells. MMAE is cleaved from cells by lysosomal protease and promotes tumor cell apoptosis by inhibiting microtubule formation. |
| Form | Liquid |
| Purity | >90% as determined by SEC. |
| Clonality | Monoclonal |
| Target | CD79b |
| Purification | Purified by Ion Exchange Chromatography. |
| Endotoxin level | Please contact with the lab for this information. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternative Names | Polivy |
| Clone ID | Polatuzumab vedotin-piiq |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Share
